Apnea Hypopnea Index

Veterans with apnea-hypopnea index scores implying no sleep apnea or severe sleep apnea had higher all-cause mortality rates vs. those with mild/moderate sleep apnea, according to data published in Annals of the American Thoracic Society.

Among patients with obstructive sleep apnea, receipt of sulthiame for 15 weeks reduced breathing pauses during sleep and daytime sleepiness, according to an abstract presented at the European Respiratory Society International Congress.

Among adults with obstructive sleep apnea receiving oral appliance therapy, mandibular jaw movement automated analysis plus monitoring may help with titration, according to results published in Annals of the American Thoracic Society.

Adults with elevated plasma homocysteine concentrations had greater apnea-hypopnea index scores, signaling more severe sleep apnea, according to results published in European Archives of Oto-Rhino-Laryngology.

SAN DIEGO — A third of patients with obstructive sleep apnea had an apnea-hypopnea index less than 10 events per hour after oral appliance therapy, according to research presented at the American Thoracic Society International Conference.

In older men, the sleep breathing impairment index definition of combined insomnia-obstructive sleep apnea predicted incident diabetes, according to results published in Annals of the American Thoracic Society.

Hypoglossal nerve stimulation reduced obstructive sleep apnea severity; however, this outcome was less likely among those with higher BMIs and those who slept in supine position, according to study results.

Patients with obstructive sleep apnea who achieved upper airway collapsibility improvement with a drug administered via nasal spray also had lower disease severity after use of the spray, according to study results.

Adding on endotype-informed targeted combination therapies to oral appliance therapy helped reduce obstructive sleep apnea severity, according to results published in Annals of the American Thoracic Society.

A combination pharmacotherapy for obstructive sleep apnea led to greater reductions in disease severity compared with placebo, according to results from a proof-of-concept phase 2 trial.